The 36-month beta value for CYTK is also noteworthy at 0.90. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 8 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for CYTK is 115.45M, and at present, short sellers hold a 12.19% of that float. The average trading volume of CYTK on March 21, 2025 was 1.53M shares.
CYTK) stock’s latest price update
The stock of Cytokinetics Inc (NASDAQ: CYTK) has decreased by -0.81 when compared to last closing price of 43.45. Despite this, the company has experienced a -2.93% fall in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-20 that Interactive Tool Harnesses Real-World Data to Visualize Burden of Disease in HCM and Advance Equitable Access to Care SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the launch of EARTH-HCM (Epidemiology, Awareness, Real-world Treatment and Health Outcomes in HCM), an online, open access, interactive public health education tool developed by Cytokinetics in collaboration with leading academic institutions, that leverages real-world, de-identified claims data to visualize and analyze population differences in patient characteristics, treatments, clinical outcomes, healthcare resource utilization and costs in hypertrophic cardiomyopathy (HCM) in the U.S. EARTH-HCM is an innovative, user-friendly, interactive tool designed to bridge the gap in awareness and education about HCM by providing insights into the treatment landscape and disparities in care.
CYTK’s Market Performance
CYTK’s stock has fallen by -2.93% in the past week, with a monthly drop of -7.11% and a quarterly drop of -12.08%. The volatility ratio for the week is 3.61% while the volatility levels for the last 30 days are 5.37% for Cytokinetics Inc The simple moving average for the past 20 days is -3.98% for CYTK’s stock, with a -16.67% simple moving average for the past 200 days.
Analysts’ Opinion of CYTK
Many brokerage firms have already submitted their reports for CYTK stocks, with Citigroup repeating the rating for CYTK by listing it as a “Buy.” The predicted price for CYTK in the upcoming period, according to Citigroup is $86 based on the research report published on February 07, 2025 of the current year 2025.
Stifel, on the other hand, stated in their research note that they expect to see CYTK reach a price target of $80. The rating they have provided for CYTK stocks is “Buy” according to the report published on January 22nd, 2025.
RBC Capital Mkts gave a rating of “Outperform” to CYTK, setting the target price at $80 in the report published on November 08th of the previous year.
CYTK Trading at -6.44% from the 50-Day Moving Average
After a stumble in the market that brought CYTK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.07% of loss for the given period.
Volatility was left at 5.37%, however, over the last 30 days, the volatility rate increased by 3.61%, as shares sank -15.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.38% lower at present.
During the last 5 trading sessions, CYTK fell by -2.93%, which changed the moving average for the period of 200-days by -11.15% in comparison to the 20-day moving average, which settled at $44.89. In addition, Cytokinetics Inc saw -8.38% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CYTK starting from Malik Fady Ibraham, who sale 2,000 shares at the price of $43.58 back on Mar 18 ’25. After this action, Malik Fady Ibraham now owns 140,455 shares of Cytokinetics Inc, valued at $87,160 using the latest closing price.
Callos Andrew, the EVP, Chief Commercial Officer of Cytokinetics Inc, sale 2,775 shares at $44.38 during a trade that took place back on Mar 17 ’25, which means that Callos Andrew is holding 34,888 shares at $123,154 based on the most recent closing price.
Stock Fundamentals for CYTK
Current profitability levels for the company are sitting at:
- -29.03 for the present operating margin
- -8.9 for the gross margin
The net margin for Cytokinetics Inc stands at -31.91. The total capital return value is set at -0.44.
Based on Cytokinetics Inc (CYTK), the company’s capital structure generated 1.21 points at debt to capital in total, while cash flow to debt ratio is standing at -0.5. The debt to equity ratio resting at -5.83. The interest coverage ratio of the stock is -6.2.
Currently, EBITDA for the company is -493.48 million with net debt to EBITDA at -1.4. When we switch over and look at the enterprise to sales, we see a ratio of 313.81. The receivables turnover for the company is 1.11for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.17.
Conclusion
In summary, Cytokinetics Inc (CYTK) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
